

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Brumskine, William Lawrence

eRA COMMONS USER NAME (credential, e.g., agency login): william.brumskine

POSITION TITLE: CRS Leader

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
University Of Limpopo, Pretoria, Gauteng	MBChB	12/2008	Bachelor of Medicine, Bachelor of Surgery
The Colleges of Medicine of South Africa	Diploma	10/2013	Diploma in HIV Management

**A. Personal Statement**

I am an ambitious and goal-oriented young researcher who would like to take a position of leadership in research of public health importance in the areas of HIV Prevention/Treatment, TB Prevention/Treatment, and Vaccine Development, in the near future.

South African trained medical doctor with a Bachelor of Medicine and Surgery, and postgraduate training in the field of HIV management, focused on the improvement of the standards of medical practise and patient care in rural and urban communities. I am the Clinical Research Site Leader and Principal Investigator on all DAIDS sponsored clinical trials at the Rustenburg Clinical Research Site. I oversee a multi-skilled staff component of 85, consisting of Medical Doctors, Professional Nurses, Social Scientists, Medical Technicians, Pharmacists, Data management professionals and administrative staff. I am responsible for the conduct of Clinical Research at the site. I ensure that the work is to the standards required by SA GCP, ICH-GCP, Protection of Human Subjects (HSP), SAHRPA and FDA requirements. I have extensive experience in clinical research management and oversight of multi-site trials, including Investigational Drug (IND) trials. I have been involved in the conduct of clinical research in HIV and TB for the past eight years, with experience as a Principal Investigator on A Phase III Microbicide Trial (FACTS 001), a Phase III Tuberculosis Treatment Trial (NC- 006- (M- Pa- Z)) and is currently the Principal Investigator on A Phase 2b Broadly Neutralizing Monoclonal Antibody Trial (HVTN 703/HPTN 081), Phase 2b/3 HIV Vaccine Trials (HVTN 705/VAC89220HPX2008, HVTN 702) and Phase III Tuberculosis Prevention Trials (WHIP3TB, CORTIS 01, A5300B/I2003B/PHOENIX). I have contributed scientifically from 2016 to 2019, to publications on the FACTS 001 study and a HIV Vaccine Preparedness Study in SA.

Prior to working in clinical trials, I was employed as a Medical Officer at the Baylor College of Medicine / Bristol Myers Squibb Children's Clinical Centre of Excellence (COE) in Maseru (from March 2011 to February 2012). Throughout my time with Baylor, my role was to provide direct clinical care at the centre for HIV infected children and adults, HIV infected pregnant women and their exposed infants (whose definitive status is unknown), and inpatient care for pediatric patients at the national referral hospital in Maseru on an intermittent basis. I also gave lectures on the comprehensive care and treatment of infants and children with HIV to visiting nurses from health facilities throughout the country and to visiting medical students and doctors from the United States and other countries. I participated in the direct supervision of the clinical work of these visiting health care professionals while they were with Baylor, ensuring that they provided excellent clinical care according to the national guidelines for HIV care in Lesotho and the clinical management guidelines outlined by the Foundation. In addition to these responsibilities, I participated in outreach activities by travelling regularly to the Thaba Tseka district of Lesotho, one of the most mountainous areas of the country. There I provided on-site lectures to nurses and other providers at health facilities in the district, as well as side-by-side mentorship and supportive supervision. My role was to provide and reinforce education on the comprehensive management of infants, children, and families with HIV, as well as the prevention of mother-to-child transmission of HIV (PMTCT). This responsibility required that I cultivate and maintained strong relationships with individual providers, representatives of local partner

organizations, the ministry of Health and Social Welfare's District health management team and District Administrators, and representatives of community-based organizations throughout the district.

I contributed to the data collection and provision of medical care on various epidemiological studies including, "A Prospective Evaluation of Clinical Outcomes and Determining Baseline Factors of Clinical Outcomes of HAART in the Pediatric Population of BIPAI Children's' Centers of Excellence in Africa".

Interests: Infectious Diseases, Clinical Trials, Public/Rural Health, Health Systems/Policy, Research Ethics, Rural Development

## **B. Positions and Honors**

### **Positions and Employment**

2009 - 2010 Medical Practitioner-Intern, Department of Health, Potchefstroom  
2011 - 2012 Medical Officer, Baylor College of Medicine Children's Foundation , Maseru  
2012 - 2013 Medical Officer/Sub-Investigator , The Aurum Institute, Rustenburg  
2013 - 2014 Medical Officer/Principal Investigator, The Aurum Institute NPC, Rustenburg  
2014 - CRS Leader, The Aurum Institute NPC, Rustenburg

### **Other Experience and Professional Memberships**

2012 - Member, Medical Malpractice for Medical Professions, Membership no-SPL/SLFG/000013724  
2009 - Member, Health Professions Council of South Africa (HPCSA), Registration no-MP 0711098

### **Honors**

Not Applicable

## **C. Contribution to Science**

1. Delany-Moretlwe Sinead, S.E., Myer Landon, Ahmed Khatija, Nkala Busi, Maboja Rebone, Gama Cynthia, Sibiyi Sydney, Sebe Modulakgotla, Brumskine William, Bekker Linda-Gail, Nchabeleng Maposhane, Lombard Carl, Gray Glenda, Rees Helen, FACTS 001: Characteristics of Participants Enrolled in a Phase III Randomised Controlled Trial of Tenofovir Gel for Prevention of HIV-1 and HSV-2. 2014, AIDS research and Human Retroviruses.p.281-A282.
2. Delany-Moretlwe S, Lombard C, Baron D, Bekker LG, Nkala B, Ahmed K, Sebe M, Brumskine W, Nchabeleng M, Palanee-Philips T, Ntshangase J, Sibiyi S, Smith E, Panchia R, Myer L, Schwartz JL, Marzinke M, Morris L, Brown ER, Doncel GF, Gray G, Rees H, Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases , Volume 18 , Issue 11 , 1241 - 1250
3. Maenetje P, Lindan C, Makkan H, M. Chetty-Makkan C, H. Latka M, Charalambous S, Mlotshwa M, Malefo M, Brumskine W, K. Hills N, A. Price M, Edward V. (2019) HIV incidence and predictors of inconsistent condom use among adult men enrolled into an HIV vaccine preparedness study, Rustenburg, South Africa. PLoS ONE 14(4): e0214786. <https://doi.org/10.1371/journal.pone.0214786>
4. Pholo Maenetje, Heeran Makkan, Candice M. Chetty-Makkan, Matshidiso Malefo, William Brumskine, Christina Lindan, Nancy K. Hills, Matthew A. Price, Vinodh Edward, HIV Risk Behaviours and HIV Incidence among High-risk Adult Men: Findings from a HIV Vaccine Preparedness Study Conducted in South Africa. 2016, AIDS Research and Human Retroviruses Vol. 32, No. S1, .p.248-P09.17.

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/1veMrjaXB-ws6q/bibliography/public/>

## **D. Additional Information: Research Support and/or Scholastic Performance**

### **Ongoing Research Support**

UM1AI068636, NIAID Churchyard; Gupta; Hesseling; Swindells (PI) 10/01/19-11/30/22  
A5300B/I2003B/PHOENIX

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB).

Role: Site PI

OPP1148133, BMGF Kublin (PI) 11/10/16-11/30/19  
HVTN 702

A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in preventing HIV-1 infection in adults in South Africa.

Role: Site PI

UM1AI068614, NIAID Corey (PI) 01/16/16-11/30/19  
HVTN 703 / HPTN 081

A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa.

Role: Site PI

5UM1AI068614-12, NIAID Kublin (PI) 12/01/18-11/30/19  
HVTN705/HPX2008

A multicenter, randomized, double-blind, placebo-controlled phase 2b efficacy study of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and aluminum phosphate-adjuvant Clade C gp140 in preventing HIV-1 infection in women in sub-Saharan Africa

Role: Co-Investigator.

AID-OAA-A-14-00029, USAID Churchyard (PI) 04/13/16-09/28/19  
WHIP3TB

A Randomised, Pragmatic, Open-Label Trial to Evaluate the Effect of three Months of High Dose Rifampin Plus Isoniazid Administered as A Single Round or Given Annually in HIV-Positive Individuals.

Role: Site PI

### **Completed Research Support**

OPP1151915, BMGF Hatherill (PI) 06/26/16-05/31/19  
CORTIS HR

Validation of Correlates of Risk of TB Disease in High Risk Populations (CORTIS HR) Validation of Correlates of Risk of TB Disease in High Risk Populations, a Companion Study of the CORTIS-01 Trial.

Role: Site PI

OPP1137034, BMGF Hatherill (PI) 10/15/15-02/28/19  
CORTIS-01

A Randomized, Partially-blinded, Clinical Trial of Isoniazid and Rifampin (3HP) Therapy to Prevent Pulmonary Tuberculosis in High-risk Individuals Identified by a Transcriptomic Correlate of Risk.

Role: Site PI